Perspectives on oncologic imaging with radiolabeled antibodies

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2431-2435

  Goldenberg, David M ^a,b  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b GARDEN STATE CANCER CENTER   (United States)

Author keywords

Nuclear imaging; Positron emission tomography; Radioimmunodetection; Radiolabeled antibodies; Radioscintigraphy

Indexed keywords

ARCITUMOMAB TC 99M; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; TECHNETIUM 99M; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER LOCALIZATION; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; LUNG CANCER; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031442657     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2431::aid-cncr15>3.0.co;2-d     Document Type: Conference Paper

References (30)

1. Parker SL, Tong T, Bolden S, Wingo P. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Fletcher SW. Why question screening mammography for women in forties. Radiol Clin North Am 1995;33:1259-71.
3. Jackson VP, Hendrick RE, Feig SA, et al. Imaging of the radiologically dense breasts. Radiology 1993;188:297-301.
4. Schmidt RA. Stereotactic core biopsy. CA Cancer J Clin 1994; 44:172-91.
5. Greenstein S, Schnall MD, Newman RW, Powell CH, Torosian MH, Rosato EF. MR imaging-guided localization and biopsy of breast lesions: initial experience. Radiology 1994;193:97-102.
6. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with radiolabelled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70.
7. Khalkhali I, Cutrone JA, Mena ID, et al. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995;196:421-6.
8. Lind P, Smola MG, Lechner P, et al. The immunoscintigraphic use of Tc-99m-labeled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991;47: 865-9.
9. Hughes K, Nabi H, Barron B, et al. Radioimmunodetection of operable breast cancer with Tc-99m-labeled anti-CEA Fab' fragment [abstract 102]. Proc Am Soc Clin Oncol 1995;14:101.
10. Rosner D, Nabi H, Panaro V, Erb D, Wild D, Hreshchyshyn M. Immunoscintigraphy may reduce the number of surgical biopsies in women with benign breast disease and indeterminate mammograms: a novel approach [abstract 75]. Proc Am Soc Clin Oncol 1996;15:102.
11. Rosner D, Nabi H, Panaro V, Goldenberg DM. Carcinoembryonic antigen immunoscintigraphy may reduce the number of surgical biopsies in women with mammographically abnormal non-palpable, benign breast disease.
12. 99mTc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997;17:40-54.
13. Moffat FL Jr., Pinsky CM, Hammershaimb L, Petrelli NJ, Patt YZ, Whaley FS, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncl 1996;14:2295-305.
14. Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg 1997;226:621-31.
15. Patt YZ, Podoloff DA, Curley S, Kasi L, Smith R, Bhadkamkar V, et al. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncl 1994;12: 489-95.
16. Dillemans B, Denegge G, Verschakelen J, et al. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non small cell lung cancer. Eur J Cardiothorac Surg 1994;8:37-42.
17. White PG, Adams H, Crane MD, et al. Preoperative staging of carcinoma of the bronchus: can computed tomographic scanning reliable to identify stage III tumors. Thorax 1994; 49:951-7.
18. Webb RW, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non small cell bronchogenic carcinoma: report of the radiologic diagnostic oncology group. Radiology 1991;178:705-13.
19. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-7.
20. Chin R Jr., Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Resp Crit Care Med 1995;152:2090-6.
21. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741-7.
22. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman D, Czernin J, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;2:94-106.
23. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996;37:1428-36.
24. Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabeled antibodies. Semin Nucl Med 1993;23:127-32.
25. Goldsmith SI. Receptor imaging: competitive or complementary to antibody imaging? Semin Nucl Med 1997;27:85-93.
26. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [In-111-DTPA-D-Phe]-and [I-123-Tyr]-octretide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1995;7:716-31.
27. Goldenberg DM. Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 1989;19:332-9.
28. Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995.
29. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 1993;73(Suppl):896-9.
30. Juweid M, Sharkey RM, Markowitz A, Behr T, Swayne LC, Dunn R, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55:5899s-907s.